Earlier in December, Regeneron Pharmaceuticals reported encouraging Phase 1/2 data for its investigational multiple myeloma ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Bispecific antibodies bring multiple tumor-cell-killing mechanisms into play simultaneously. When a T cell is activated and ...

The Investment Committee debate the latest Calls of the Day. Lawmakers react to US seizure of Venezuelan oil tanker 'Taylor ...

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a Phase 2 study ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Biocon Biologics inks settlement and license agreement to commercialize biosimilar aflibercept worldwide: Our Bureau, Bengaluru Monday, December 15, 2025, 16:45 Hrs [IST] Biocon B ...

Berlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...